Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DANAHER CORPORATION

(DHR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Danaher : 3Q Profit, Sales Rise

10/22/2020 | 06:40am EDT

By Dave Sebastian

Danaher Corp.'s profit and sales for the third quarter grew, the company said Thursday.

For the quarter ended Oct. 2, the conglomerate on Thursday posted net income before preferred dividends of $883.5 million, or $1.16 a share, compared with $668 million, or 84 cents a share, in the year-ago period.

One of the company's units earlier this month said its Covid-19 antibody test got emergency use authorization from the Food and Drug Administration. The company didn't immediately provide details of Covid-19 effects in its earnings release Thursday.

Adjusted earnings were $1.72 a share. Analysts polled by FactSet were looking for earnings of $1.01 a share, or $1.36 a share on an adjusted basis.

Sales rose to $5.88 billion from $4.38 billion in the comparable quarter last year. Analysts were looking for $5.51 billion. Core revenue, including Cytiva, rose 14%. The company had expected third-quarter core revenue growth, including Cytiva, to be in the mid- to high-single digit range.

Danaher said it expects fourth-quarter core revenue growth, including Cytiva, to be in the low-double digit range.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

10-22-20 0639ET

All news about DANAHER CORPORATION
07/23DANAHER : Goldman Sachs Adjusts Danaher's Price Target to $320 from $280, Keeps ..
MT
07/23DANAHER : JPMorgan Adjusts Danaher's Price Target to $310 from $280, Keeps Overw..
MT
07/23DANAHER : Wells Fargo Adjusts Danaher's Price Target to $320 from $290, Keeps Ov..
MT
07/23DANAHER : Baird Adjusts Danaher's Price Target to $305 From $270, Reiterates Out..
MT
07/23DANAHER : RBC Boosts Price Target on Danaher to $304 From $285, Reiterates Secto..
MT
07/23DANAHER : UBS Adjusts Danaher's Price Target to $322 From $302, Citing 2021 Guid..
MT
07/23DANAHER : Barclays Adjusts Danaher's Price Target to $335 From $310, Maintains O..
MT
07/22Danaher Raises 2021 Adjusted Core-Revenue Outlook
DJ
07/22Danaher 2Q Sales Rise, Beating Analyst Expectations
DJ
07/22DANAHER : Posts Higher Q2 Earnings, Sales; Revises 2021 Core Revenue Growth Outl..
MT
More news
Financials (USD)
Sales 2021 28 511 M - -
Net income 2021 5 942 M - -
Net Debt 2021 11 039 M - -
P/E ratio 2021 36,2x
Yield 2021 0,31%
Capitalization 208 B 208 B -
EV / Sales 2021 7,68x
EV / Sales 2022 7,21x
Nbr of Employees 68 000
Free-Float 74,1%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | DHR | US2358511028 | MarketScreener
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 291,27 $
Average target price 312,21 $
Spread / Average Target 7,19%
EPS Revisions
Managers and Directors
Rainer M. Blair President, Chief Executive Officer & Director
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Steven M. Rales Chairman
Jose Carlos Gutiérrez Ramos Chief Science Officer & Senior Vice President
Brian W. Ellis Senior Vice President & General Counsel
Sector and Competitors